A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
Ozkaynak, M. Fevzi, Gilman, Andrew L., London, Wendy B., Naranjo, Arlene, Diccianni, Mitchell B., Tenney, Sheena C., Smith, Malcolm, Messer, Karen S., Seeger, Robert, Reynolds, C. Patrick, Smith, L. MТом:
9
Мова:
english
Журнал:
Frontiers in Immunology
DOI:
10.3389/fimmu.2018.01355
Date:
June, 2018
Файл:
PDF, 1.81 MB
english, 2018
File converter
Більше результатів пошуку
More benefits 
